Abstract
Glucocorticoid-induced osteoporosis (GIO) is the most common secondary cause of osteoporosis. The use of glucocorticoid (GC) is associated with an increase in bone loss, especially at vertebral spine, and risk of fracture. Active vitamin D(3) (VD(3)) is expected to preserve bone mineral density at vertebral spine, however it is inferior to bisphosphonates (BP) with respect to preventing incidental vertebral fractures. In the guidelines on the management and treatment of GIO in Japan, VD(3) is recommended as the second-lined drug for GIO. The combination of VD(3) and BP is thought to be a beneficial therapy in prevention and or treatment of GIO.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
